Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025 DOI Open Access
Ruth Link‐Gelles,

Sean Chickery,

A Webber

et al.

MMWR Morbidity and Mortality Weekly Report, Journal Year: 2025, Volume and Issue: 74(6), P. 73 - 82

Published: Feb. 27, 2025

COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2024-2025 vaccine, which targets Omicron JN.1 JN.1-derived sublineages. Interim effectiveness of vaccines was estimated against COVID-19-associated emergency department (ED) or urgent care (UC) visits September 2024-January 2025 among adults ≥18 years in one CDC-funded vaccine (VE) network, hospitalization immunocompetent ≥65 two networks, with immunocompromising conditions network. Among years, VE ED/UC 33% (95% CI = 28%-38%) first 7-119 days after vaccination. from estimates were 45% 36%-53%) 46% 26%-60%) 40% 21%-54%) These findings demonstrate dose provides additional protection encounters compared not receiving support current ACIP recommendations dose.

Language: Английский

Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025 DOI Open Access
Ruth Link‐Gelles,

Sean Chickery,

A Webber

et al.

MMWR Morbidity and Mortality Weekly Report, Journal Year: 2025, Volume and Issue: 74(6), P. 73 - 82

Published: Feb. 27, 2025

COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2024-2025 vaccine, which targets Omicron JN.1 JN.1-derived sublineages. Interim effectiveness of vaccines was estimated against COVID-19-associated emergency department (ED) or urgent care (UC) visits September 2024-January 2025 among adults ≥18 years in one CDC-funded vaccine (VE) network, hospitalization immunocompetent ≥65 two networks, with immunocompromising conditions network. Among years, VE ED/UC 33% (95% CI = 28%-38%) first 7-119 days after vaccination. from estimates were 45% 36%-53%) 46% 26%-60%) 40% 21%-54%) These findings demonstrate dose provides additional protection encounters compared not receiving support current ACIP recommendations dose.

Language: Английский

Citations

1